Law No. 17 of 2026 created a longevity regulator that sits beside the DHA, and some of what your wellness or regenerative lines already do may now fall under it.

Law No. 17 of 2026 was signed on 6 June 2026 and published in the Official Gazette on 13 June. Article 27 brings it into force on the date of publication, so the Dubai Longevity Authority's remit has been operative since 13 June.

The Authority sits beside the DHA rather than inside it, and Article 2 defines the Activity it governs as advanced and applied therapies, research and development with laboratory and clinical trials, therapeutic and preventive services, and the promotion, marketing, sale or distribution of longevity products.

If your group runs anti-ageing, IV-wellness, regenerative or cell-therapy lines, or distributes the products those lines use, the question is no longer only whether you hold a DHA facility licence.

One point of housekeeping. Article 1 titles the law in Arabic with a name that renders literally as Dubai Health Sustainability Authority, against the English Dubai Longevity Authority. Both are official and the pair is not a literal translation, so the Gulf News rendering followed the gazetted Arabic rather than mistaking this body for another one. Use whichever form matches the language of the document you are drafting.

Leadership was set quickly. Decree No. 14 of 2026 named Sheikh Hamdan bin Mohammed as President, and Decree No. 15 of 2026 named Helal Saeed Almarri as Chairman. Article 2 lists the Concerned Entities the Authority coordinates with: the DHA, Dubai Academic Health Corporation, the Department of Economy and Tourism, and Dubai Municipality.

That last pairing is the tell. Almarri is Director General of the Department of Economy and Tourism, and its presence beside the clinical regulators says the Authority is being built as an economic instrument as much as a health one.

Article 7(a) prohibits any natural or legal person from carrying on the Activity in Dubai without a permit from the Authority, and it says so expressly for the special development zones and the free zones, the DIFC among them. There is no transitional or grandfathering article anywhere in the law's 27 articles.

What has not issued is the board resolution that sets the permit conditions and procedures under that same article. Read those two facts together and the position is uncomfortable rather than comfortable: the requirement binds today, and the route to satisfying it is not open. Reading the gap as a grace period is the error to avoid.

Take each thing you offer and place it against the language of the definition. Some services sit clearly under the DHA and are unlikely to move. Some read plainly as longevity. A meaningful set will be ambiguous, and that ambiguous middle is where your regulatory and commercial risk concentrates. Two structural points sharpen the exercise.

Under Article 8 the Authority permits facilities while the DHA continues to permit individual professionals, and the Authority's approval is required before those professional permits issue, so the two licences are sequenced rather than parallel. And under Article 19 the Authority may suspend a permit for up to six months, or cancel it and coordinate with the commercial licensing authority to cancel the trade licence with it. The exposure is not a fine; it is the company.

A regenerative or cell-therapy asset priced on a DHA basis may be re-scoped under a stricter framework, and the licensing path drives both the timeline to revenue and the multiple you can defend. Any thesis in Dubai longevity or wellness written after 13 June 2026 that does not ask which authority governs the target's core service lines is carrying an unpriced risk.

Location in a free zone does not answer the question: Article 7(a) reaches the free zones and the DIFC by name, so a Dubai Healthcare City or DIFC address is not a perimeter defence. The same logic runs the other way for the well-prepared, and a clean, permit-anticipating position is becoming a value driver in a sector Dubai has openly decided to lead.

The interval before the permit conditions land is short, and it is not dead time. Operators who use it to map their lines and assemble the evidence a science-led reviewer would expect will set their positioning before the framework hardens around them. The first credible files an authority reviews often shape how the ambiguous categories get read. That is worth more than the cost of preparing early, and unlike a grace period it is a real advantage rather than an assumed one.